Drug Farm today announced the successful first closing of its $55 million Series D financing. The financing round was co-led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise, with participation from new investors Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing investors, including BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas, also participated in the round.
The proceeds from the financing will support the continued advancement of Drug Farm’s clinical and preclinical stage pipeline, accelerate global clinical development programs, strengthen regulatory activities across key markets, and further expand the company’s research and development capabilities.
“The successful completion of this financing represents an important milestone in Drug Farm’s mission to develop first-in-class drugs for the world. We are pleased to welcome our new investors while receiving continued support from our long-term shareholders, reflecting strong confidence in the company’s scientific innovation, development strategy, and long-term vision. We believe this financing positions Drug Farm to create significant value for patients, partners, and shareholders in the years ahead,” said Dr. Tian Xu, Founder and Chairman of Drug Farm.
Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, added, “We are delighted to complete this financing and grateful for the continued confidence and support from our investors. We are proud that DF-003 is amongst the first drugs developed with AI and entering a Phase 3 trial. The investment provides additional resources to advance DF-003 through the completion of a pivotal trial in patients with ROSAH syndrome and clinical proof of concept in atherosclerotic cardiovascular disease. The funds will also be used to continue clinical development of DF-006 in patients with hepatitis B.”
Dr. Tony Xu, Chief Operating Officer of Drug Farm, commented, “Powered by IDInVivo+ and MedChem5, our proprietary platforms combining genetics and artificial intelligence continues to discover and validate novel drug targets and rapidly advance multiple first-in-class candidates into the clinic. This financing will help us bring additional breakthrough therapies to patients with unmet needs in metabolic and autoimmune diseases.”
About Drug Farm
Drug Farm is a private biotechnology company developing innovative treatments for ROSAH syndrome, heart and kidney diseases, hepatitis B, and metabolic diseases. Its proprietary IDInVivo+ platform integrates genetics and artificial intelligence to identify and validate novel drug targets directly in living systems. Drug Farm is advancing multiple first-in-class drug candidates developed by its proprietary AI platform MedChem5 into clinical development.
For more information, please visit: https://www.drug-farm.com.
About DF-003
DF-003 is a proprietary, first-in-class drug developed by Drug Farm’s MedChem5 platform that inhibits the activity of ALPK1 and its disease-causing variants. DF-003 has demonstrated evidence of clinical improvement across multiple symptoms of ROSAH syndrome in an ongoing Phase 1b study (NCT06395285). DF-003 is amongst the first drugs developed with AI that will enter a Phase 3 trial. DF-003 also has therapeutic potential for heart and kidney diseases based on efficacy observed in preclinical models. DF-003 has received Fast Track, Orphan Drug, Rare Pediatric Disease, Rare Disease Evidence Principles designations from the FDA. The discovery of DF-003 has been published in Nature Communications.
About DF-006
DF-006 is a proprietary, first-in-class orally administered ALPK1 agonist immunomodulator that potently stimulates local, innate immunity in the liver. DF-006 has successfully completed single and multiple ascending dose (MAD) evaluation in healthy volunteers, and MAD evaluation in virologically suppressed HBeAg negative chronic hepatitis B (CHB) patients where encouraging anti-HBV activity was observed. The discovery of DF-006 has been published in Hepatology. Drug Farm and Xiamen Amoytop Biotech Co., Ltd. have entered into a clinical collaboration for DF-006 to treat hepatitis B and hepatocellular cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260713078455/en/
Media gallery
